• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Hillstream BioPharma Inc. (Amendment)

    2/14/24 4:00:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HILS alert in real time by email
    SC 13G/A 1 j117244sc13ga1.htm AMENDMENT NO. 1

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)* 

     

    Tharimmune, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    432705200

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 pages 
     

     

    CUSIP No. 432705200

     

     

    13G/A Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    pN 

     

     Page 2 of 8 pages 
     

     

    CUSIP No. 432705200

     

     

    13G/A Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0% 

    12

    type of reporting person

     

    OO 

     

     Page 3 of 8 pages 
     

     

    CUSIP No. 432705200

     

     

    13G/A Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang 

    2 Check the Appropriate Box if a Member of a Group*
    (
    a) ¨
    (b) x
    3 SEC Use Only
    4

    Citizenship or Place of Organization

     

    united states 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

      8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Tharimmune, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    1200 Route 22 East, Suite 2000, Bridgewater, NJ 08807

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 432705200

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 pages 
     

     

    (b)Percent of Class:

     

    Tang Capital Partners 0.0%
    Tang Capital Management 0.0%
    Kevin Tang 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares
       
    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

     

     

    Date:   February 14, 2024  

     

     

    TANG CAPITAL PARTNERS, LP  
         
    By: Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $HILS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HILS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HILS
    SEC Filings

    View All

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    2/8/24 4:05:29 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events

    8-K - Tharimmune, Inc. (0001861657) (Filer)

    12/12/23 4:15:16 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Inc. filed SEC Form 8-K: Other Events (Amendment)

    8-K/A - Tharimmune, Inc. (0001861657) (Filer)

    12/11/23 6:15:17 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/18/23 10:04:37 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/4/23 4:15:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Milby Randy bought $14,587 worth of shares (29,000 units at $0.50), increasing direct ownership by 23% to 156,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/18/23 10:04:37 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milby Randy bought $10,000 worth of shares (10,000 units at $1.00), increasing direct ownership by 9% to 127,517 units (SEC Form 4)

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    12/4/23 4:15:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Bui Lynne A.

    4 - Tharimmune, Inc. (0001861657) (Issuer)

    11/9/23 7:55:53 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc.

    Expects to launch and complete a Phase 1 trial in Q4 2023Tharimmune to begin trading under new ticker, THAR, on Monday September 25, 2023BRIDGEWATER, NJ / ACCESSWIRE / September 22, 2023 / Hillstream BioPharma Inc., (NASDAQ:HILS), a biotechnology company developing innovative therapeutic candidates in rare immune, inflammatory and oncologic diseases announced a corporate name change to Tharimmune, Inc., ("Tharimmune"). The corporate name change is based on the Greek word "thárros", translated to mean courage and reflects the transformation of the Company into a patient-focused, clinical development organization. The Company's common stock will trade on The Nasdaq Capital Market under a new t

    9/22/23 8:30:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis

    Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of moderate to severe chronic pruritis in which more than 70% of patients suffer from chronic pruritis BRIDGEWATER, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancer announces an exclusive option agreement to acquire a clinical stage asset, AV104, with a recently approved IND. AV104 has a dual mechanism of action by affecting multiple rec

    9/11/23 11:51:49 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

    Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers with immuno-oncology targeted novel biologics, today announced that it will be presenting at the H.C. Wainwright 25th Annual Global Investment Conference, being held in person and virtually from September 11-13, 2023. Event: H.C. Wainwright Presentation On-DemandDate: September 11th, 2023Time: 7:00am ETRegistration: Link *Please note that Company presentation

    9/8/23 2:30:00 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Leadership Updates

    Live Leadership Updates

    View All

    Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics

    Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect and proprietary novel bovine-derived biologic platform, PicoKnobTM, targeting undruggable epitopes on PD-1 and TROP2 Experienced biopharmaceutical executive joins as Chief Operating Officer to spearhead execution of ADC and biologic strategy BRIDGEWATER, N.J., July 10, 2023 (GLOBE NEWSWIRE) --  Hillstream BioPharma (NASDAQ:HILS) a biotechnology company developing innovative therapeutic candidates targeting drug resistant and devastating cancers that can make a difference in patients' lives,

    7/10/23 8:47:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson

    BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (NASDAQ:HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting drug resistant and devastating cancers using ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death, and immuno-oncology targeted novel biologics, today announced the appointment of Kelly Anderson to its Board of Directors and committees, effective as of May 9, 2023. Mrs. Anderson brings over 25 years of experience in public company finance, accounting and corporate governance across a variety of industries and will be instrumental in guiding Hillstream with its or

    5/15/23 8:47:00 AM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HILS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Hillstream BioPharma Inc. (Amendment)

    SC 13G/A - Tharimmune, Inc. (0001861657) (Subject)

    2/14/24 4:00:21 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Hillstream BioPharma Inc.

    SC 13G - Tharimmune, Inc. (0001861657) (Subject)

    12/7/23 4:00:10 PM ET
    $HILS
    Biotechnology: Pharmaceutical Preparations
    Health Care